The aortic valve study was led by Sabine Bleiziffer, MD, consultant cardiac surgeon, German Heart Center Munich, Munich, Germany, and will be presented as a poster abstract (TCT-111) on Tuesday, September 22 between 8:00 a.m. and 10:00 a.m. in Hall D of The Moscone Center.
"Transcatheter aortic valve implantation with the self-expandable prosthesis is an effective and durable treatment for patients with aortic stenosis not eligible for surgical aortic valve replacement," said Dr. Bleiziffer.
Between June 2007 and April 2009, 179 aortic valve prostheses were implanted in non-surgical candidates via a number of different routes: transfemoral (164 patients), transapical (5 patients), subclavian artery (7 patients), and ascending aorta (3 patients). Patients were a mean age of 81 ± 7y, with a mean STS score of 19 ± 11% and symptomatic high-grade aortic stenosis (mean valve orifice area 0.7 ± 0.2cm², mean aortic gradient 48 ± 18 mm Hg).
Periprocedural complications included femoral access site complications in 13% of the patients, dialysis for postoperative renal failure in 8%, neurologic events in 7%, and permanent pacemaker implantation in 26%. 30 day-, 6 months-, and 1 year-survival was 88%, 78%, and 78%, respectively.
Freedom from bleeding events, thromboembolic events, structural valve deterioration and prosthestic endocarditis was 83%, 97%, 99% and 97% at one year. Non-structural valve deterioration or valve thrombosis did not occur. Mean aortic gradient decreased to 11 ± 4 mm Hg (valve size 26) and 12 ± 4 mm Hg (valve size 29), and valve orifice area increased to 1.4 ± 0.4cm² (valve size 26) and 1.5 ± 0.3cm² without change up to one-year follow-up.
The study concluded that multiple vascular access sites are feasible for implantation of the prosthesis because of the small diameter of the delivery sheath. Periprocedural complications are considerable but related to the high risk patient population. Mid-term valve-related complications are exceptionally low and the gradient release after prosthesis implantation is stable up to one year of follow-up.
"A close and careful follow-up of patients treated with the new technology of transcatheter valve implantation including history of valve-related complications and echocardiographic assessment is crucial to approve the quality of the technique and to redefine indications for future patients," said Dr. Bleiziffer.
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in the subspecialty of interventional cardiology and endovascular medicine.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field of interventional cardiology and vascular medicine.
Judy Romero | EurekAlert!
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences